Overall, our findings suggested that combining osimertinib with a VEGF or VEGFR inhibitor could be an effective strategy for EGFR-mutated advanced NSCLC patients, though optimal administration of anti-angiogenic agents warrants further investigation. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.